Aura Biosciences, Inc..
AURA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Aura Biosciences, Inc. is a biotechnology company focused on developing a novel class of therapies to selectively target and destroy cancer cells. Their lead product candidate, AU-011 (belzupacap sarotalocan), is a first-in-class targeted therapy in development for the treatment of primary choroidal...Show More
Better Health for All
50
Aura Biosciences is a biotechnology company entirely focused on developing novel therapies for life-threatening cancers, including primary choroidal melanoma and non-muscle invasive bladder cancer (NMIBC). This dedication to developing treatments for high unmet medical needs aligns with a strong positive health impact. The company's entire business model is devoted to health improvement through its pipeline. All of the company's R&D and capital allocation is directed towards developing these therapies, which means 100% of its investment is aimed at improving health outcomes. Early Phase 1 data for its lead candidate, belzupacap sarotalocan, showed 80% complete responses in intermediate-risk NMIBC patients and 20% in high-risk patients with light activation.
1
Fair Money & Economic Opportunity
0
No evidence available to assess Aura Biosciences, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative data points were found across the provided articles to score Aura Biosciences against most of the defined KPIs for Fair Pay & Worker Respect. The articles explicitly state no information is available for living wage coverage, CEO-to-median employee pay ratio, collective bargaining share, safety incident rates, pay equity ratios, worker engagement scores, turnover rates, insecure contract share, or health insurance coverage.
1
For labor violation incidents, the articles consistently report no information on regulatory actions, violations, fines, or compliance issues, which aligns with the 'N/A – no public record of labour-law breaches' tier.
2
Fair Trade & Ethical Sourcing
-10
Aura Biosciences states that supplier agreements require compliance with all laws prohibiting forced labor, human trafficking, and child labor.
1
Suppliers are also required to certify that materials provided comply with applicable laws regarding slavery, human trafficking, and fair labor standards.
2
Additionally, suppliers and business partners must observe the Anti-Bribery and Anti-Corruption Policy and the Human Rights Policy.
3
The company has a policy to give diverse suppliers an equal opportunity in their strategic sourcing and procurement process, with objectives including actively seeking certified diverse suppliers and ensuring their inclusion.
4
However, less than 1% of the procurement budget is directed to local, indigenous, or minority suppliers.
Honest & Fair Business
0
The provided articles, which are 8-K filings summarizing the 2025 Annual Meeting, do not contain specific, quantifiable evidence for any of the KPIs related to Honest & Fair Business.
1
The filings explicitly state that they are focused solely on the results of the annual meeting and do not include broader ESG or compliance issues.
2
Therefore, no KPIs can be scored based on the available information.
Kind to Animals
-70
Aura Biosciences, Inc. uses animals for preclinical studies, as evidenced by the generation of preclinical data using an orthotopic animal model for its lead product candidate, AU-011.
1
This indicates that no validated non-animal methods are employed, and the company relies on in vivo tests. Consequently, not a single product is certified cruelty-free.
2
The company's policy on animal testing is evidenced by its use of animal models for preclinical data, but no specific policy details are provided, indicating a vague or unstated policy where routine non-essential testing continues.
3
No War, No Weapons
0
No information was found in the provided articles regarding Aura Biosciences, Inc.'s involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other activities related to the 'No War, No Weapons' ethical value.
1
Information presented in one article pertained to a different company and was therefore not considered for Aura Biosciences, Inc.
2
Planet-Friendly Business
-20
Aura Biosciences achieved carbon neutrality for its 2022 Scope 1 and 2 emissions, which was independently verified by SCS Global Services.
1
The company intends to maintain carbon neutrality going forward.
2
In 2023, 42% of its total energy usage came from renewable sources, with a target to reach 60% by 2027.
3
Aura invested in carbon offset projects, including landfill gas-to-power, forestry, wind energy, and solar, which were verified by SCS Global Services.
4
The company sourced an average of 40% of its purchases from local suppliers.
5
No environmental compliance violations were mentioned in the provided articles.
Respect for Cultures & Communities
0
The provided articles do not contain any specific, concrete data points or facts relevant to Aura Biosciences, Inc.'s performance regarding 'Respect for Cultures & Communities'.
1
The articles primarily focus on corporate profile, financial information, product development, and general ESG risk ratings without detailing community engagement, cultural impact assessments, local employment, or any other specific metrics outlined in the rubric for this value.
2
Safe & Smart Tech
-40
The company's privacy policy, last updated in June 2025, allows users to opt out of marketing communications and provides information on blocking cookies and opting out of Google Analytics.
1
However, it explicitly states that the company does not respond to 'Do Not Track' signals, which represents a significant limitation on user control over data tracking.
2
The company collects various types of data, including contact details, communications, device data, and usage data.
3
While the company states it collects data to provide and improve services, promote the business, and for compliance, there is no specific evidence of defined retention periods or strict necessity tests for data collection, suggesting limited data minimization practices.
4
Aura Biosciences is subject to comprehensive regulation by the FDA and other regulatory agencies, including state and foreign data protection laws like GDPR.
5
The company maintains physical and electronic security for its IT systems and employs technical, organizational, and physical safeguards to protect personal information, though it acknowledges no security measures are failsafe.
6
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles for any of the Key Performance Indicators related to Zero Waste & Sustainable Products. The articles primarily focus on financial performance, clinical trial updates, regulatory designations, general ESG risk ratings, and carbon neutrality goals, which are not directly relevant to waste management or sustainable product metrics.